title: Haemoglobin dynamics in Papuan and non-Papuan adults in northeast Papua, Indonesia, with acute, uncomplicated vivax or falciparum malaria.
abstract: BACKGROUND
  Haemoglobin (Hb) recovers slowly in malaria and may be influenced by naturally acquired immunity. Hb recovery was compared in malaria immune, indigenous Papuan and non-Papuan adults with limited malaria exposure.
  
  
  METHODS
  Hb concentrations were measured on Days (D) 0, 3, 7, and 28 in 57 Papuans and 105 non-Papuans treated with chloroquine, doxycycline or both drugs for acute, uncomplicated Plasmodium vivax (n = 64) or Plasmodium falciparum (n = 98).
  
  
  RESULTS
  Mean (SD, range) D0 Hb was 12.7 (2.2, 7–21.3) g/dL and was similar in P. falciparum infected Papuans and non-Papuans: 12.2 vs. 12.8 g/dL (P = 0.15) but significantly lower in: (i) P. vivax-infected Papuans vs. P. vivax-infected non-Papuans: 11.4 vs. 13.47 g/dL [Δ = −2.07 (95% CI: –3.3 – –0.8), P = 0.0018], (ii) all patients with splenomegaly (vs. those without splenomegaly): 12.16 vs. 13.01 g/dL [Δ = −0.85 (−1.6– –0.085), P = 0.029], and (iii) all females vs. all males: 10.18 vs. 13.01 g/dL [Δ = −2.82 (−3.97 – –1.67), P < 0.0001].Multiple regression identified female sex (P = 0.000), longer illness duration (P = 0.015) (P. falciparum patients) and Papuan ethnicity (P = 0.017) (P. vivax patients) as significant factors for a lower D0 Hb. Mean D28 Hb increased to 13.6 g/dL [Δ = 1.01 (0.5-1.5) vs. D0 Hb, P = 0.0001]. It was: (i) positively correlated with the D0 Hb (adjusted R2 = 0.24, P = 0.000), and was significantly lower in P. vivax infected Papuans vs. non-Papuans: 12.71 vs. 14.46 g/dL [Δ = −1.7 (−2.95– –0.5, P = 0.006).
  
  
  CONCLUSIONS
  Haemoglobin recovery was related to baseline Hb. Vivax-infected malaria immune Papuans had persistently lower Hb concentrations compared to non-Papuans with limited malaria exposure. This haematological disadvantage remains unexplained.
authors.affiliation: The US Navy Medical Research Unit no. 2-NAMRU-2, Jakarta, Indonesia. bob@tropmedres.ac
authors.forename: Walter R J
authors.initials: WR
authors.lastname: Taylor
authors.forename: Hendra
authors.initials: H
authors.lastname: Widjaja
authors.forename: Hasan
authors.initials: H
authors.lastname: Basri
authors.forename: Emiliana
authors.initials: E
authors.lastname: Tjitra
authors.forename: Colin
authors.initials: C
authors.lastname: Ohrt
authors.forename: Taufik
authors.initials: T
authors.lastname: Taufik
authors.forename: Samuel
authors.initials: S
authors.lastname: Baso
authors.forename: Stephen L
authors.initials: SL
authors.lastname: Hoffman
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Richie
mesh_terms: D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000473:pathology*; D000962:Antimalarials / Q000008:administration & dosage*; D002738:Chloroquine / Q000008:administration & dosage; D004318:Doxycycline / Q000008:administration & dosage; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007214:Indonesia; D016778:Malaria, Falciparum / Q000150:complications* / Q000188:drug therapy*; D016780:Malaria, Vivax / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000962:Antimalarials; D006454:Hemoglobins; D002738:Chloroquine; D004318:Doxycycline